About

We conduct clinical trials and observational studies in the areas of brain and spine disorders. This includes memory loss, dementia, stroke, Parkinson’s disease and spinal cord injury. Our neuroscience research teams work through  Struthers Parkinson's Center and the Center for Memory & Aging.  An additional area of focus is on intranasal drug delivery.

Affiliation
people
Faculty Position
  • Barclay, Terry R., PhD, LP, Research investigator, Center for Memory & Aging, Regions Hospital 2009 -
  • Fine, Jared M., PhD, Research Associate 2006 -
  • Frey II, William H., PhD, Sr. Director 1977 -
  • Guliani, Gaurav K., MD, Research Investigator
  • Hanson, Leah R., PhD, Sr. Director
  • Herrmann, Amanda A., PhD, Research Associate 2021 -
  • Jackson, Steven D., MD, Research Investigator
  • Johnson, Julia C, MD, Research Investigator
  • Kashyap, Bhavani, MBBS, PhD, Research Associate 2017 -
  • Nance, Martha A., MD, Research Investigator
  • Parashos, Sotirios A., MD, PhD, Research Investigator
  • Rosenbloom, Michael H., MD, Director 2010 -
  • Wyman-Chick, Kate A., PsyD, ABPP, Investigator and Clinical Neuropsychologist at HealthPartners Neuroscience Center
  • Publications
    selected publications
    Journal Article
  • Assessment of deep brain stimulation candidacy during the COVID-19 pandemic: lessons learned and future directions for neuropsychologists
    Clinical Neuropsychologist. 2022
  • Brief visuospatial memory test-revised normative data and form equivalency for adults ages 80-89
    Clinical Neuropsychologist. 2022
  • Patterns and predictors of extra-corporeal membrane oxygenation related cerebral microbleeds
    Journal of Stroke and Cerebrovascular Diseases. 2022
  • Prodromal dementia with Lewy bodies: evolution of symptoms and predictors of dementia onset
    Journal of Geriatric Psychiatry and Neurology. 2022
  • Rate and predictors of acute care encounters in the first month after stroke
    Journal of Stroke and Cerebrovascular Diseases. 2022
  • Readmission to an acute care hospital during inpatient rehabilitation after stroke
    American Journal of Physical Medicine and Rehabilitation. 2022
  • Responding to the needs of persons living with dementia and their caregivers during the COVID-19 pandemic: lessons from the Care Ecosystem
    Innovation in aging. 2022
  • A phase II, single-center, randomized, double-blind, placebo-controlled study of the safety and therapeutic efficacy of intranasal glulisine in amnestic mild cognitive impairment and probable mild Alzheimer's disease
    Drugs and Aging. 2021
  • A retrospective study evaluating the use of anti-Parkinsonian medications in patients with advanced Parkinson’s disease who are treated with Levodopa-Carbidopa Intestinal Gel and deep brain stimulation: the PD-DUAL Study
    Neurology. 2021
  • Barriers to achieving target door-to-needle time in patients treated with IV thrombolysis
    Healthc Res J. 2021
  • Cognitive effects of aerobic exercise in Alzheimer's disease: a pilot randomized controlled trial
    Journal of Alzheimer's Disease. 2021
  • Comparative effectiveness of intracerebroventricular, intrathecal, and intranasal routes of AAV9 vector administration for genetic therapy of neurologic disease in murine mucopolysaccharidosis type I
    Frontiers in Molecular Neuroscience. 2021
  • Longitudinal change in quality of life in neurological disorders measures over 3 years in patients with early Parkinson's disease
    Movement Disorders. 2021
  • Losartan improves memory, neurogenesis and cell motility in transgenic Alzheimer's mice
    Pharmaceuticals (Basel, Switzerland). 2021
  • Nasal oxytocin for the treatment of psychiatric disorders and pain: achieving meaningful brain concentrations
    Translational psychiatry. 2021
  • Neuropsychological test performances and depression in early-stage de novo Parkinson's disease
    Archives of Clinical Neuropsychology. 2021
  • A successful quality improvement project for detection and management of acute stroke in hospitalized patients
    Journal of Neuroscience Nursing. 2020
  • Antifibrotic effects of amyloid-beta and Its loss in cirrhotic liver
    Cells. 2020
  • Cell motility and migration as determinants of stem cell efficacy
    EBioMedicine. 2020
  • Double-blind placebo-controlled pilot investigation of the safety of a single dose of rapid-acting intranasal insulin in Down syndrome
    Drugs in R&D. 2020
  • Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists
    Genetics in Medicine. 2020
  • Intranasal deferoxamine can improve memory in healthy C57 mice, suggesting a partially non-disease-specific pathway of functional neurologic improvement
    Brain and behavior. 2020
  • Intranasal delivery of low-dose insulin ameliorates motor dysfunction and dopaminergic cell death in a 6-OHDA rat model of Parkinson's Disease
    Neuroscience Letters. 2020
  • Intranasal delivery of thyroid hormones in MCT8 deficiency
    PloS One. 2020
  • Quality improvement in Parkinson's disease: a successful program to enhance timely administration of Levodopa in the hospital
    Journal of Parkinson's Disease. 2020
  • Recommendations for the organization of multidisciplinary clinical care teams in Parkinson's disease
    Journal of Parkinson's Disease. 2020
  • Tract-specific analysis improves sensitivity of spinal cord diffusion MRI to cross-sectional and longitudinal changes in amyotrophic lateral sclerosis
    Communications biology. 2020
  • Transforming dementia care through pragmatic clinical trials embedded in learning healthcare systems
    Journal of the American Geriatrics Society. 2020
  • Adherence to pharmacotherapy in patients with Parkinson's disease taking three and more daily doses of medication
    Frontiers in Neurology. 2019
  • Assessment of the performance of a modified motor scale as applied to juvenile onset Huntington's disease
    2019
  • End-of-life measures in Huntington disease: HDQLIFE meaning and purpose, concern with death and dying, and end of life planning
    Journal of Neurology. 2019
  • Feasibility trial of a 10-week adaptive yoga intervention developed for chronic pain patients
    Pain Management Nursing. 2019
  • From A to D: a unique case report of recovery after longitudinal myelitis related to lupus
    American Journal of Physical Medicine and Rehabilitation. 2019
  • Intranasal coadministration of a diazepam prodrug with a converting enzyme results in rapid absorption of diazepam in rats
    Journal of Pharmacology and Experimental Therapeutics. 2019
  • Intranasal losartan decreases perivascular beta amyloid, inflammation, and the decline of neurogenesis in hypertensive rats
    Neurotherapeutics. 2019
  • Neurochemical correlates of functional decline in amyotrophic lateral sclerosis
    Journal of Neurology, Neurosurgery and Psychiatry. 2019
  • Quantifying intranasally administered deferoxamine in rat brain tissue with mass spectrometry
    ACS Chemical Neuroscience. 2019
  • Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial
    Neurology. 2019
  • Solitary bone plasmacytoma compression injury disguised as back pain: a case report
    2019
  • Unique case report of a meningeal sarcoma arising during ongoing treatment for progressing intraparenchymal glioma
    2019
  • Use and perceived effectiveness of complementary therapies in Parkinson's disease
    Parkinsonism & Related Disorders. 2019
  • A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning
    Journal of Neurology. 2018
  • Agreement between clinician-rated versus patient-reported outcomes in Huntington disease
    Journal of Neurology. 2018
  • Executive function: responses to aerobic exercise in Alzheimer's disease
    Geriatric Nursing (New York, N.Y.). 2018
  • Frontotemporal lobe degeneration as origin of scans without evidence of dopaminergic deficit
    Frontiers in Neurology. 2018
  • Neuropsychological test performance in Parkinsonism without dopaminergic deficiency on [123I]-FP-CIT SPECT imaging
    Journal of the International Neuropsychological Society. 2018
  • Pharmacokinetics in rat of P8, a peptide drug candidate for the treatment of Alzheimer's disease: stability and delivery to the brain
    Journal of Alzheimer's disease reports. 2018
  • Pooled analyses of phase III studies of ADS-5102 (Amantadine) extended-release capsules for dyskinesia in Parkinson's disease
    2018
  • Rates of abnormally low TOPF word reading scores in individuals failing versus passing performance validity testing
    Assessment. 2018
  • Rescue therapies for seizure emergencies: new modes of administration
    Epilepsia. 2018
  • Screening positive for cognitive impairment: impact on healthcare utilization and provider action in primary and specialty care practices
    Journal of General Internal Medicine. 2018
  • Selection of normative group affects rates of mild cognitive impairment in Parkinson's disease
    Movement Disorders. 2018
  • What predicts falls in Parkinson disease? Observations from the Parkinson's Foundation registry
    2018
  • A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
    Neurology. 2017
  • A survey-based study identifies common but unrecognized symptoms in a large series of juvenile Huntington's disease
    Neurodegenerative Disease Management. 2017
  • Diagnostic accuracy and confidence in the clinical detection of cognitive impairment in early-stage Parkinson disease
    Journal of Geriatric Psychiatry and Neurology. 2017
  • Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort
    Journal of the Neurological Sciences. 2017
  • Genetics of Huntington disease
    Handbook of Clinical Neurology. 2017
  • Intranasal adeno-associated virus mediated gene delivery and expression of human iduronidase in the central nervous system: a noninvasive and effective approach for prevention of neurologic disease in mucopolysaccharidosis Type I
    Human Gene Therapy. 2017
  • Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease
    Journal of the Neurological Sciences. 2017
  • Intranasal delivery of a novel amnion cell secretome prevents neuronal damage and preserves function in a mouse multiple sclerosis model
    Scientific Reports. 2017
  • Intranasal insulin treatment of an experimental model of moderate traumatic brain injury
    Journal of Cerebral Blood Flow and Metabolism. 2017
  • NMDA receptor antibody encephalitis presenting with enhancing lesion and seizures
    2017
  • National randomized controlled trial of virtual house calls for Parkinson disease
    Neurology. 2017
  • Oxytocin enhances observational fear in mice
    Nature communications. 2017
  • Reliability and validity of the HD-PRO-TriadTM, a health-related quality of life measure designed to assess the symptom triad of Huntington's disease
    2017
  • Research priorities to advance the health and health care of older adults with multiple chronic conditions
    Journal of the American Geriatrics Society. 2017
  • Clinical-genetic associations in the Prospective Huntington at Risk Observational Study (PHAROS): implications for clinical trials
    JAMA neurology. 2016
  • Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1
    Parkinsonism & Related Disorders. 2016
  • Food consumption and activity levels increase in rats following intranasal Hypocretin-1
    Neuroscience Letters. 2016
  • HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD)
    Quality of Life Research. 2016
  • HDQLIFE: the development of two new computer adaptive tests for use in Huntington disease, speech difficulties, and swallowing difficulties
    Quality of Life Research. 2016
  • Health care delivery practices in Huntington's disease specialty clinics: an international survey
    2016
  • Intranasal delivery of obidoxime to the brain prevents mortality and CNS damage from organophosphate poisoning
    Neurotoxicology. 2016
  • Intranasal drug delivery bypasses the blood–brain barrier
    2016
  • MECR mutations cause childhood-onset dystonia and optic atrophy, a mitochondrial fatty acid synthesis disorder
    American Journal of Human Genetics. 2016
  • National randomized controlled trial of virtual house calls for people with Parkinson's disease: Interest and barriers
    Telemedicine Journal and e-Health. 2016
  • New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system)
    Quality of Life Research. 2016
  • Oxytocin receptor: expression in the trigeminal nociceptive system and potential role in the treatment of headache disorders
    Cephalalgia. 2016
  • Routine cognitive screening in a neurology practice: effect on physician behavior
    2016
  • Susac syndrome with prominent dermatological findings and a prompt response to intravenous immunoglobulin, steroids, and rituximab: a case report
    2016
  • The impact of oculomotor functioning on neuropsychological performance in Huntington disease
    Journal of Clinical and Experimental Neuropsychology. 2016
  • Can biomarkers differentiate pain and no pain subgroups of nonverbal children with cerebral palsy? A preliminary investigation based on noninvasive saliva sampling
    Pain Medicine. 2015
  • Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial
    JAMA. 2015
  • Huntington disease
    2015
  • Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation
    Neuroscience Letters. 2015
  • Intranasal delivery of therapeutic neural stem cells to target intracerebral glioma
    2015
  • Managing residents with Parkinson's disease in long-term care
    2015
  • Metabolic disorders with clinical and radiologic features of sporadic Creutzfeldt-Jakob disease
    2015
  • Motor onset and diagnosis in Huntington disease using the diagnostic confidence level
    Journal of Neurology. 2015
  • Noninvasive intranasal stem cells bypass the blood-brain barrier to target the brain to treat Parkinson's disease, stroke, MS, brain tumors, cerebral ischemia, Alzheimer's and other CNS disorders
    2015
  • Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial
    Lancet Neurology. 2015
  • Sex differences in clinical features of early, treated Parkinson's disease
    PloS One. 2015
  • The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study
    Movement Disorders. 2015
  • Validation of an ambulatory capacity measure in Parkinson disease: a construct derived from the Unified Parkinson's Disease Rating Scale
    Journal of Parkinson's Disease. 2015
  • . 2008;157:908-25]
    Neuroscience. 2014
  • . 2012 Jan 11;8:3]
    Molecular Pain. 2014
  • A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein e4 carriers with mild-moderate Alzheimer's disease
    2014
  • Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD Study
    Frontiers in Aging Neuroscience. 2014
  • Clinical, demographic, and pharmacologic features of nursing home residents with Huntington's disease
    Journal of the American Medical Directors Association. 2014
  • Cognitive and motor function in long-duration PARKIN-associated Parkinson disease
    JAMA neurology. 2014
  • Experience, knowledge, and opinions about childhood genetic testing in Batten disease
    Molecular Genetics and Metabolism. 2014
  • Eye-specific gene expression following embryonic ethanol exposure in zebrafish: roles for heat shock factor 1
    Reproductive Toxicology. 2014
  • Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial
    JAMA neurology. 2014
  • Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer's and Parkinson's disease
    Cell Transplantation. 2014
  • Intranasal delivery, a quick and effective way to deliver therapeutics to the brain
    AAPS (American Association of Pharmaceutical Scientists) Newsmagazine. 2014
  • Intranasal insulin: a potential therapeutic for post-traumatic stress disorder and Alzheimer's
    Minn Physician. 2014
  • Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinsons disease
    Brain Research. 2014
  • Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience
    JAMA neurology. 2014
  • Mobility, mood and site of care impact health related quality of life in Parkinson's disease
    Parkinsonism & Related Disorders. 2014
  • Post-traumatic stress disorder: new approach may help prevent, as well as treat, this devastating disorder
    2014
  • Treatment of myoclonus-dystonia syndrome with tetrabenazine
    Parkinsonism & Related Disorders. 2014
  • Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset
    Neurogenetics. 2013
  • Falls in Parkinson disease: analysis of a large cross-sectional cohort
    Journal of Parkinson's Disease. 2013
  • Intranasal administration of CNS therapeutics to awake mice
    Journal of visualized experiments. 2013
  • Managing juvenile Huntington's disease
    Neurodegenerative Disease Management. 2013
  • Mindfulness-based stress reduction for family caregivers: a randomized controlled trial
    The Gerontologist. 2013
  • CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion
    Neurology. 2012
  • Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study
    Neurology. 2012
  • Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region
    American Journal of Human Genetics. 2012
  • Comparison of central versus peripheral delivery of pregabalin in neuropathic pain states:
    Molecular Pain. 2012
  • Detection of postoperative sleep-disordered breathing using a portable monitoring device
    Sleep & breathing = Schlaf & Atmung. 2012
  • Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1alpha, and phosphorylates GSK3beta in P301L tau transgenic mice
    Experimental Brain Research. 2012
  • Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice
    Drug delivery and translational research. 2012
  • Intranasal delivery of growth differentiation factor 5 to the central nervous system
    Drug delivery. 2012
  • Intranasal delivery of insulin via the olfactory nerve pathway
    Journal of Pharmacy and Pharmacology. 2012
  • Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway
    Neuroscience Letters. 2012
  • Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration
    Molecular Genetics and Metabolism. 2012
  • Population stratification may bias analysis of PGC-1alpha as a modifier of age at Huntington disease motor onset
    Human Genetics. 2012
  • Special delivery: intranasal treatments bypass blood-brain barrier to treat Alzheimer's and other brain disorders
    Minn Physician. 2012
  • Subacute intranasal administration of tissue plasminogen activator increases functional recovery and axonal remodeling after stroke in rats
    Neurobiology of Disease. 2012
  • TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease
    Biochemical and Biophysical Research Communications. 2012
  • The functional neuroanatomy of decision-making
    Journal of Neuropsychiatry and Clinical Neurosciences. 2012
  • Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution
    Neurology. 2011
  • Ethanol-induced microphthalmia is not mediated by changes in retinoic acid or sonic hedgehog signaling during retinal neurogenesis
    Alcoholism, Clinical and Experimental Research. 2011
  • Genetic testing in clinical practice
    Continuum (Minneapolis, Minn.). 2011
  • Impulsive behavior and associated clinical variables in Parkinson's disease
    Psychosomatics. 2011
  • Intranasal delivery of CNS therapeutics
    AAPS (American Association of Pharmaceutical Scientists) Newsmagazine. 2011
  • Intranasal delivery of caspase-9 inhibitor reduces caspase-6-dependent axon/neuron loss and improves neurological function after stroke
    Journal of Neuroscience. 2011
  • Intranasal phosphoramidon increases beta-amyloid levels in wild-type and NEP/NEP2-deficient mice
    Journal of Molecular Neuroscience. 2011
  • Motor end plate innervation loss in diabetes and the role of insulin
    Journal of Neuropathology and Experimental Neurology. 2011
  • Neuropsychological profile of parkin mutation carriers with and without Parkinson disease: the CORE-PD Study
    Journal of the International Neuropsychological Society. 2011
  • Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study
    Neurology. 2011
  • Recruiting and retaining family caregivers to a randomized controlled trial on mindfulness-based stress reduction
    Contemporary Clinical Trials. 2011
  • Safety and tolerability of galantamine SA in dementia patients transitioned from donepezil
    Consultant Pharmacist. 2011
  • Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment
    Brain. 2011
  • Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease
    Rejuvenation research. 2011
  • Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain
    Molecular Pain. 2010
  • Challenges assessing clinical endpoints in early Huntington disease
    Movement Disorders. 2010
  • Donepezil-associated bradyarrhythmia in a patient with dementia with Lewy bodies (DLB)
    Alzheimer Disease and Associated Disorders. 2010
  • Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study
    Archives of Neurology. 2010
  • Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS
    Journal of Drug Targeting. 2010
  • Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study
    Archives of Neurology. 2010
  • Production and fate of the sea lamprey migratory pheromone
    Fish Physiology and Biochemistry. 2010
  • Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease
    Rejuvenation research. 2010
  • Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease
    Journal of Clinical and Experimental Neuropsychology. 2010
  • Sexual and relationship satisfaction among persons with young-onset Parkinson's disease
    Journal of Sexual Medicine. 2010
  • Striatal and white matter predictors of estimated diagnosis for Huntington disease
    Brain Research Bulletin. 2010
  • Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures
    Molecular Pharmaceutics. 2010
  • Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience
    Archives of Neurology. 2009
  • Human and rodent amyloid-beta peptides differentially bind heme: relevance to the human susceptibility to Alzheimer's disease
    Archives of Biochemistry and Biophysics. 2009
  • Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke
    Journal of Pharmacology and Experimental Therapeutics. 2009
  • Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system
    Journal of Pharmaceutical Sciences. 2009
  • Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system
    Journal of Pharmacology and Experimental Therapeutics. 2009
  • Prominent phenotypic variability associated with mutations in Progranulin
    Neurobiology of Aging. 2009
  • A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease
    Parkinsonism & Related Disorders. 2008
  • Delivery of interferon-beta to the monkey nervous system following intranasal administration
    Neuroscience. 2008
  • Elements of attention in HIV-infected adults: evaluation of an existing model
    Journal of Clinical and Experimental Neuropsychology. 2008
  • Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study
    Neurology. 2008
  • Intranasal administration delivers peptoids to the rat central nervous system
    Neuroscience Letters. 2008
  • Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone
    BMC Neuroscience. 2008
  • Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults
    Journal of Alzheimer's Disease. 2008
  • Neurocognition in individuals co-infected with HIV and hepatitis C
    Journal of Addictive Diseases. 2008
  • New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163
    Neuro-Oncology. 2008
  • Replication of association between ELAVL4 and Parkinson disease: the GenePD study
    Human Genetics. 2008
  • The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study
    BMC Medicine. 2008
  • Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease
    Brain. 2007
  • Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families
    Movement Disorders. 2007
  • Verbal episodic memory declines prior to diagnosis in Huntington's disease
    Neuropsychologia. 2007
  • A new locus for dominant hereditary spastic paraplegia maps to chromosome 2p12
    Neurogenetics. 2006
  • Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study
    BMC Medical Genetics. 2006
  • Mutations in the novel mitochondrial protein REEP1 cause hereditary spastic paraplegia type 31
    American Journal of Human Genetics. 2006
  • Falls and injuries resulting from falls among patients with Parkinson's disease and other parkinsonian syndromes
    Movement Disorders. 2005
  • Inhibition of ligand binding to G protein-coupled receptors by arachidonic acid
    Journal of Molecular Neuroscience. 2005
  • Antigliadin antibodies in Huntington's disease
    Neurology. 2004
  • Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease
    Clinical Neuropharmacology. 2004
  • Intragenic modifiers of hereditary spastic paraplegia due to spastin gene mutations
    Neurogenetics. 2004
  • Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis
    Journal of Neuroimmunology. 2004
  • The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats
    Journal of Stroke and Cerebrovascular Diseases. 2004
  • A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study
    American Journal of Human Genetics. 2003
  • Association study of Parkin gene polymorphisms with idiopathic Parkinson disease
    Archives of Neurology. 2003
  • Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease
    Neurology. 2003
  • Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease
    Human Molecular Genetics. 2003
  • Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease
    American Journal of Medical Genetics. Part A. 2003
  • Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease
    American Journal of Human Genetics. 2003
  • Parkin mutations and susceptibility alleles in late-onset Parkinson's disease
    Annals of Neurology. 2003
  • Predictors of nursing home placement in Huntington disease
    Neurology. 2003
  • Seeking clarity through the genetic lens: a work in progress
    Annals of Neurology. 2003
  • Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer's brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants
    Brain Research. 2002
  • Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion
    Neuroscience Letters. 2001
  • Inconsistency between severe substantia nigra degeneration with Lewy bodies and clinical parkinsonism in dementia patients: a cliniconeuropathological study
    Acta Neuropathologica. 2000
  • Pure hippocampal sclerosis: a rare cause of dementia mimicking Alzheimer's disease
    Neurology. 2000
  • Endogenous Alzheimer's brain factor and oxidized glutathione inhibit antagonist binding to the muscarinic receptor
    Brain Research. 1996
  • Quantitative analysis of the olfactory pathway for drug delivery to the brain
    Brain Research. 1995
  • Clinical characteristics of chronic Creutzfeldt-Jakob disease
    Journal of Geriatric Psychiatry and Neurology. 1994
  • Free D-amino acids in human cerebrospinal fluid of Alzheimer disease, multiple sclerosis, and healthy control subjects
    Molecular and Chemical Neuropathology. 1994
  • Inhibitor of antagonist binding to the muscarinic receptor is elevated in Alzheimer's brain
    Brain Research. 1994
  • Seizures in Alzheimer's disease: clinicopathologic study
    Journal of Geriatric Psychiatry and Neurology. 1994
  • Serum cytokine levels in patients with Alzheimer's disease
    Clinical and Diagnostic Laboratory Immunology. 1994
  • Transforming growth factor beta in Alzheimer's disease
    Clinical and Diagnostic Laboratory Immunology. 1994
  • Two cases of acute anti-GM1 antibody elevations in response to exogenous GM1 without neurological symptoms
    Journal of Neuroimmunology. 1994
  • Pick's disease versus Alzheimer's disease: a comparison of clinical characteristics
    Neurology. 1993
  • Silica-ELISA method improves detection and quantitation of minor glycolipid components in lipid mixtures and of other antigens
    Journal of Immunological Methods. 1993
  • A clinicopathological study of CT scans in Alzheimer's disease
    Journal of the American Geriatrics Society. 1992
  • Altered aspartate in Alzheimer neurofibrillary tangles
    Neurochemical Research. 1992
  • Clinically diagnosed Alzheimer disease: neuropathologic findings in 650 cases
    Alzheimer Disease and Associated Disorders. 1992
  • Deletion in the prion protein gene in a demented patient
    Human Molecular Genetics. 1992
  • Multiple sclerosis dementia
    Neurology. 1992
  • Racemized D-aspartate in Alzheimer neurofibrillary tangles
    Brain Research Bulletin. 1992
  • Risk factors in Alzheimer's disease: a clinicopathologic study
    Neurology. 1992
  • Neuropathologically confirmed Alzheimer's disease: clinical diagnoses in 394 cases
    Journal of Geriatric Psychiatry and Neurology. 1991
  • Seasonal distribution of births in Alzheimer's disease
    International Psychogeriatrics. 1991
  • Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia
    Neurology. 1990
  • GM-1 treatment of Alzheimer's disease. A pilot study of safety and efficacy
    Archives of Neurology. 1990
  • Immunogold labeling of Alzheimer paired helical filaments with ganglioside MAB A2B5
    Alzheimer Disease and Associated Disorders. 1990
  • D-aspartate in human brain
    Journal of Neurochemistry. 1987
  • Ganglioside monoclonal antibody (A2B5) labels Alzheimer's neurofibrillary tangles
    Neurology. 1987
  • Glial fibrillary acidic protein and Alzheimer's disease
    Neurochemical Research. 1985
  • Human brain tubulin purification: decrease in soluble tubulin with age
    Neurochemical Research. 1985
  • A comparison of peripheral and central human muscarinic cholinergic receptor affinities for psychotropic drugs
    Biological Psychiatry. 1982
  • Postmortem stability of dopamine-sensitive adenylate cyclase, guanylate cyclase, ATPase, and GTPase in rat striatum
    Journal of Neurochemistry. 1981
  • Stimulation of guanylate cyclase by EDTA and other chelating agents
    Biochimica et Biophysica Acta. 1981
  • Effect of dopamine on activation of rat striatal adenylate cyclase by free Mg2+ and guanyl nucleotides
    Journal of Neurochemistry. 1980
  • Chapter
  • Comportment: structure and function
    Neurology and Neuropsychiatry. 2013
  • Conference Poster
  • Outcomes of an embedded resource and education program for patients and families with memory loss [poster]
    2017
  • Performance on cognitive screening is associated with increased retrospective healthcare utilization [poster]
    2015
  • Pharmacokinetics of a diazepam prodrug/enzyme combination following nasal administration in rats for treatment of seizure emergencies [poster]
    2015
  • Routine cognitive screening in a neurology practice: impact on physician behavior [poster]
    2015
  • The Minnesota Memory Project: baseline data from a longitudinal observational study of aging [poster]
    2015
  • Failure on cognitive screening predicts increased healthcare utilization [poster]
    2014
  • Routine cognitive screening in a general neurology clinic: impact on physician behavior [poster]
    2014
  • Detection of deferoxamine using liquid chromatography/mass spectrometry with electrospray ionization [poster]
    2013
  • Evidence-based provider tools for efficient identification and management of cognitive impairment [poster]
    2013
  • Intranasally administered deferoxamine induces neuroprotection in a 6-OHDA model of Parkinson's disease [poster]
    2013
  • Intranasally administered deferoxamine induces neuroprotection in a 6-OHDA model of Parkinson's disease [poster]
    2013
  • Lavender essential oil improved sleep in residents of a memory care assisted living facility [poster]
    2013
  • The effect of intranasal rapid acting insulin on ApoE4 carriers with mild-moderate Alzheimer's disease [poster]
    2013
  • Feasibility of the mini-cog as a standardized cognitive screen in HealthPartners patients aged 70 and older [poster]
    2012
  • Intranasal deferoxamine treatment in a rat model of Parkinsons disease: preliminary results [poster]
    2012
  • Pedicle screw fixation in cervical trauma [poster]
    2012
  • Specific types of memory complaints may provide an early warning sign of cognitive impairment in community dwelling older adults [poster]
    2012
  • The 6th Vital Sign Project: does cognitive screening in the elderly population improve clinical care [poster]?
    2012
  • Tractography of the human cervical spine nerve roots [poster]
    2012
  • Review
  • Brain glucose hypometabolism and iron accumulation in different brain regions in Alzheimer's and Parkinson's diseases [review]
    Pharmaceuticals (Basel, Switzerland). 2022
  • Mechanisms of intranasal deferoxamine in neurodegenerative and neurovascular disease [review]
    Pharmaceuticals (Basel, Switzerland). 2021
  • The global pandemic has permanently changed the state of practice for pre-DBS neuropsychological evaluations [review]
    Parkinsonism & Related Disorders. 2021
  • Integrated care in Parkinson's disease: a systematic review and meta-analysis [meta-analysis, review, systematic review]
    Movement Disorders. 2020
  • Intranasal insulin: a treatment strategy for addiction [review]
    Neurotherapeutics. 2020
  • Does cognitive training prevent cognitive decline: a systematic review [systematic review]
    Annals of Internal Medicine. 2018
  • Over-the-counter supplement interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review [systematic review]
    Annals of Internal Medicine. 2018
  • Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review [systematic review]
    Annals of Internal Medicine. 2018
  • Physical activity interventions in preventing cognitive decline and Alzheimer-type dementia: a systematic review [systematic review]
    Annals of Internal Medicine. 2018
  • Genetic counseling and testing for Huntington's disease: a historical review [review]
    American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics. 2017
  • Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer's-type dementia [review]
    2017
  • Oxytocin and migraine headache [review]
    Headache. 2017
  • Disability rating scales in Parkinson's disease: Critique and recommendations [review]
    Movement Disorders. 2016
  • Creutzfeldt-Jakob Disease in the hospital setting: a case report and review [review]
    Minnesota Medicine. 2013
  • Incomplete nonsense-mediated decay facilitates detection of a multi-exonic deletion mutation in SGCE [review]
    Clinical Genetics. 2013
  • Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence [review]
    2013
  • Intranasal insulin to treat and protect against posttraumatic stress disorder [review]
    Journal of Nervous and Mental Disease. 2013
  • Intranasal treatment of central nervous system dysfunction in humans [review]
    Pharmaceutical Research. 2013
  • Brain insulin signaling and Alzheimer's disease: current evidence and future directions [review]
    Molecular Neurobiology. 2012
  • Intranasal treatment of neurodegenerative diseases and stroke [review]
    Frontiers in bioscience (Scholar edition). 2012
  • Therapy in Huntington's disease: where are we [review]?
    Current Neurology and Neuroscience Reports. 2012
  • Intranasal insulin as a therapeutic option in the treatment of cognitive impairments [review]
    Experimental Gerontology. 2011
  • The evaluation of rapidly progressive dementia [review]
    The neurologist. 2011
  • Intranasal delivery to the central nervous system: mechanisms and experimental considerations [review]
    Journal of Pharmaceutical Sciences. 2010
  • Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease [review]
    BMC Neuroscience. 2008
  • Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS [review]
    Journal of Neuroimmune Pharmacology. 2007
  • Abstract
  • A retrospective study evaluating the use of anti-Parkinsonian medications in patients with advanced Parkinson's disease treated with Levodopa-Carbidopa Intestinal Gel and deep brain stimulation [abstract]
    Journal of the Neurological Sciences. 2021
  • IMPACT Learning Health Network: transforming care through embedded pragmatic clinical trials in health care settings that serve people with dementia [abstract]
    Journal of patient-centered research and reviews. 2021
  • The NIA IMPACT Collaboratory: transforming dementia care rhrough embedded pragmatic clinical trials [abstract]
    2020
  • Implementation of a mindfulness based dementia-care program within a healthcare system [abstract]
    Innovation in aging. 2019
  • Chord Study: the power of music through participation in the giving voice chorus [abstract]
    Alzheimer's & dementia. 2018
  • Correlation between evaluation and documentation of neurologic deficit by EMS and ED of patients with acute ischemic stroke [abstract]
    Neurology. 2018
  • Analysis of run sheets of EMS serving a metropolitan comprehensive stroke center [abstract]
    Neurology. 2017
  • Clinical characteristics and healthcare utilization of Hmong patients presenting with stroke [abstract]
    Neurology. 2017
  • Clinical characteristics of Hmong patients presenting with acute ischemic stroke [abstract]
    Stroke. 2017
  • Cognitive screening results from the Medicare annual wellness visit in a primary care practice [abstract]
    Alzheimer's & dementia. 2017
  • Mindfulness for early Alzheimer's Disease: a pilot study [abstract]
    Alzheimer's & dementia. 2017
  • The Twin Cities ALS Research Consortium: a model for regional collaboration in advancing research for people living with ALS [abstract]
    2017
  • Minnesota memory project: use of the Alberta Smell Test in a longitudinal aging cohort [abstract]
    Alzheimer's & dementia. 2016
  • Outcomes from routine cognitive screening in a health care system [abstract]
    Alzheimer's & dementia. 2016
  • Outcomes of a dementia resource and education program imbedded in a health care system [abstract]
    Alzheimer's & dementia. 2016
  • Delivery of therapeutics via the intranasal route for the treatment of neurodegenerative diseases [abstract]
    Neurotherapeutics. 2015
  • Nasal delivery of lidocaine decreases carrageenan-induced orofacial pain [abstract 1782]
    2011
  • Quick Info